The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
CETUXICOL, a phase II trial randomizing standard treatment with or without cetuximab in primary cervical cancer treatment.
Suzy Marie Elisabeth Scholl
No relevant relationships to disclose
Anne De la Rochefordiere
No relevant relationships to disclose
Peter Petrow
No relevant relationships to disclose
Anne Floquet
No relevant relationships to disclose
Thierry Petit
No relevant relationships to disclose
Severine Alran
No relevant relationships to disclose
Dominique Berton-Rigaud
No relevant relationships to disclose
Maura Campitelli
No relevant relationships to disclose
Claire Chiara-Bruneaud
No relevant relationships to disclose
Michel Fabbro
No relevant relationships to disclose
Virginie Fourchotte
No relevant relationships to disclose
Frederic Guyon
No relevant relationships to disclose
Florence Joly
No relevant relationships to disclose
Christine Kerr
No relevant relationships to disclose
Sophie Maillard
No relevant relationships to disclose
Mathieu Minsat
No relevant relationships to disclose
Corine Plancher
No relevant relationships to disclose
Marius Pop
No relevant relationships to disclose
Xavier Sastre
No relevant relationships to disclose
Philippe Beuzeboc
No relevant relationships to disclose